E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

Highlights of Day 2 at ASCO19

Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.

June 2, 2019
E

Tackling immunosuppression with a dual approach to TIGIT and adenosine

Do we need to target the adenosine fog as well as TIGIT in NSCLC?

June 24, 2021
E

ASCO21 Off the Beaten Track Part 2

A look at some hidden gems in the ASCO program and what it all means in terms of the science.

May 27, 2021
E

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021
E

A case to answer

Every now and again something intriguing comes along, which generates a flurry of interest from our…

February 17, 2021
E

On finding new targets and boosting existing therapies

Science drives oncology new product development and the AACR special conferences are always a good place…

October 22, 2020
E

ASGCT20 Gems from the ePoster Hall

Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20

May 14, 2020
E

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020
E

Highlights from small biotechs at SITC 2019

Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider

November 12, 2019
E

What’s new with Corvus Pharma?

New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...

June 11, 2019
E

Can AZN take immuno-oncology to the next level?

Through the keyhole with a look at AZN and MedImmune's IO portfolio

April 25, 2017
E

Targeting the adenosine pathway in cancer immunotherapy

A look a the updated adenosine pathway landscape and how it is progressing

April 18, 2019
E

Corvus CPI-444 Data Disappoints at AACR 2017

Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.

April 5, 2017
E

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016
E

Innate Pharma at an Inflexion Point: An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016